Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric D Jacobsen

Showing results (21-30 of 48) with videos related to

Pageof 5
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 18, 2008
Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcomePhilippe Armand, Haesook T Kim, Vincent T Ho, et al.
Leukemia & Lymphoma|November 22, 2016
Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistryNancy L Bartlett, Mitchell R Smith, Tanya Siddiqi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 13, 2008
Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioningPhilippe Armand, Supriya Gannamaneni, Haesook T Kim, et al.
Blood|July 12, 2019
Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemiaPhilipp B Staber, Marco Herling, Mar Bellido, et al.
Blood Advances|November 15, 2024
A real-world comparison of commercial-use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphomaAndrew Looka, David A Qualls, Daniel Matthews, et al.
British Journal of Haematology|November 19, 2014
A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphomaFrancine Foss, Ranjana Advani, Madeleine Duvic, et al.
The Lancet. Haematology|December 19, 2018
Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b studyMatthew S Davids, Haesook T Kim, Alyssa Nicotra, et al.
Blood Advances|May 13, 2026
Clofarabine for relapsed/refractory Langerhans cell (LC) and non-LC histiocytosisBarbara A Degar, Oussama Abla, Patrick K Campbell, et al.
Leukemia|January 30, 2023
A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemiaChristine E Ryan, Danielle M Brander, Paul M Barr, et al.
Leukemia & Lymphoma|February 21, 2024
Effect of atorvastatin versus placebo on efficacy in patients with diffuse large B-cell lymphoma receiving R-CHOPRonald Nemec, Marielle Scherrer-Crosbie, Jeremy S Abramson, et al.
Pageof 5

Showing results (21-30 of 48) with videos related to

Sort By:
Pageof 5
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 18, 2008
Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcomePhilippe Armand, Haesook T Kim, Vincent T Ho, et al.
Leukemia & Lymphoma|November 22, 2016
Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistryNancy L Bartlett, Mitchell R Smith, Tanya Siddiqi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 13, 2008
Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioningPhilippe Armand, Supriya Gannamaneni, Haesook T Kim, et al.
Blood|July 12, 2019
Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemiaPhilipp B Staber, Marco Herling, Mar Bellido, et al.
Blood Advances|November 15, 2024
A real-world comparison of commercial-use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphomaAndrew Looka, David A Qualls, Daniel Matthews, et al.
British Journal of Haematology|November 19, 2014
A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphomaFrancine Foss, Ranjana Advani, Madeleine Duvic, et al.
The Lancet. Haematology|December 19, 2018
Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b studyMatthew S Davids, Haesook T Kim, Alyssa Nicotra, et al.
Blood Advances|May 13, 2026
Clofarabine for relapsed/refractory Langerhans cell (LC) and non-LC histiocytosisBarbara A Degar, Oussama Abla, Patrick K Campbell, et al.
Leukemia|January 30, 2023
A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemiaChristine E Ryan, Danielle M Brander, Paul M Barr, et al.
Leukemia & Lymphoma|February 21, 2024
Effect of atorvastatin versus placebo on efficacy in patients with diffuse large B-cell lymphoma receiving R-CHOPRonald Nemec, Marielle Scherrer-Crosbie, Jeremy S Abramson, et al.
Pageof 5